Anti-Daratumumab (DARZALEX) ELISA Assay Kit
The Anti-Daratumumab (DARZALEX) ELISA Assay Kit is For Research Use Only
Size: 12×8 wells
Sensitivity: +/-
Incubation Time: 2 hours 20 minutes
Sample Type: Serum, Plasma
Sample Size: 20 µl
Alternative Name: Darzalex
Assay Background
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. Subcutaneous daratumumab with hyaluronidase is also indicated alone or in combination for the treatment of multiple myeloma. Daratumumab is a monoclonal antibody that targets and induces apoptosis in cells that highly express CD38, including multiple myeloma cells. It has a long duration of action as it is given every 1-4 weeks. Patients should be counselled regarding the risk of hypersensitivity, neutropenia, thrombocytopenia, embryo-fetal toxicity, and interferences with cross-matching and red blood cell antibody screening.
Assay Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Controls and samples (serum or plasma) are incubated in the microtiter plate coated with the drug Atezolizumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to Daratumumab antibodies captured by the drug Atezolizumab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of Daratumumab antibodies in the sample or controls. The results can be evaluated with using cut-off value.
Related Products
Daratumumab ELISA Assay Kit
Anti-Infliximab ELISA Assay Kit
Anti-Etanercept ELISA Assay Kit
